Nanjing Leads Biolabs jumps on progress of tumor antibody treatment
BUZZ-Nanjing Leads Biolabs jumps on progress of tumor antibody treatment ** Shares of Nanjing Leads Biolabs 9887.HK jump 8.3% to HK$62.85, the highest level since July 24
** Stock of the China-based oncology therapies developer set for the biggest one-day pct gain since July 15
** Company says Phase II clinical study evaluating its bispecific antibody PD-L1/4-1BB and Opamtistomig (LBL-024) for treatment of first-line hepatocellular carcinoma (HCC), or malignant tumor, has completed safety run in phase assessment review and has successfully entered expansion phase
** Preliminary data show that Opamtistomig in combination with bevacizumab has demonstrated encouraging efficacy signals in patients with HCC with a favorable overall safety profile and good tolerability - co
** YTD, stock up 23.1%, Hang Seng Biotech Index .HSBIO up 1.5%
(Reporting by Donny Kwok)
Recent news on Nanjing Leads Biolabs
See all newsBrief: Nanjing Leads Biolabs Says FDA Grants Fast Track Designation To LBL-024
Brief: Nanjing Leads Biolabs Posts HY Loss Attributable RMB221.9 Million
Nanjing Leads rises on clinical study progress on cancer treatment drug
Nanjing Leads Biolabs jumps on progress of tumor antibody treatment
Nanjing Leads Biolabs rises on NMPA's IND approval for colorectal cancer